CTOs on the Move


 
Opiant Pharmaceuticals` team of industry and addiction experts are dedicated developing treatments for addiction, overdose, and related disorders for the mass market. Our first product NARCAN® Nasal Spray became available in the United States and Canada through our commercial partner, Adapt Pharma.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.opiant.com
  • 233 Wilshire Boulevard Suite 280
    Santa Monica, CA USA 90401
  • Phone: 424.252.4756

Executives

Name Title Contact Details

Similar Companies

Havas Health and You

Havas Health & You is a unique health and wellness network focused on promoting healthy living decisions across the entire health ecosystem. We believe in putting YOU – our employees, business partners, and our customers – at the center of everything we do. By understanding what you need and crafting unique solutions, we can help you stay and live well.

Vision RT

Vision RT is the inventor of Surface Guided Radiation Therapy (SGRT) and produces a range of innovative solutions to improve radiation therapy.

ASP Global

We help you reach your savings targets and your patient experience goals by designing and delivering supplies and patient care products.

Cytovia Therapeutics

Cytovia is dedicated to the development of transformational cancer immunotherapies, addressing several of the most challenging unmet medical needs including the prevention of cancer relapse and metastasis. Cytovia focuses on Natural Killer (NK) cell biology and applies precision medicine tools to develop the right therapy for the right patient at the right stage of the disease. Cytovia has secured access to multiple advanced technologies, including allogeneic cell therapy, multispecific antibodies, and cytokines. Cytovia establishes development partnerships to accelerate time-to-market and commercialization alliances in order to optimize rapid adoption of its novel immunotherapies.

Nevakar

Nevakar is a specialty pharmaceutical company, focused on developing innovative products in injectable and ophthalmic space. Our goal is to develop enhanced products that address unmet clinical and/or commercial needs of currently [FDA] approved molecules, through intensive R&D and clinical efforts.